Prime Medicine (PRME) Change in Accured Expenses (2021 - 2026)

Prime Medicine (PRME) has 6 years of Change in Accured Expenses data on file, last reported at -$4.5 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 32.35% year-over-year to -$4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $993000.0 (up 394.66% YoY) and the FY2025 annual result came in at -$1.2 million, down 162.94% from the prior year.
• Change in Accured Expenses retreated to -$4.5 million in Q1 2026, from $1.6 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $5.9 million in Q3 2024 to a low of -$33.3 million in Q1 2022.
• A 5-year average of -$1.6 million and a median of $608000.0 in 2023 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 1211.11% in 2025, down 118.06% in 2025.
• Tracing PRME's Change in Accured Expenses over 5 years: stood at $4.1 million in 2022, then tumbled by 38.53% to $2.5 million in 2023, then sank by 105.73% to -$144000.0 in 2024, then soared by 1211.11% to $1.6 million in 2025, then sank by 381.38% to -$4.5 million in 2026.
• The last three Change in Accured Expenses figures came in at -$4.5 million (Q1 2026), $1.6 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.